We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.6%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.35B
AUM Growth
+$157M
Cap. Flow
+$100M
Cap. Flow %
7.42%
Top 10 Hldgs %
27.65%
Holding
142
New
12
Increased
63
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.7M
2
CI icon
Cigna
CI
+$11.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.4M
4
CLSD
Clearside Biomedical
CLSD
+$9.46M
5
HOLX
Hologic
HOLX
+$7.96M

Top Sells

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$32.7M
2
ELV icon
Elevance Health
ELV
+$16.8M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$9.49M
4
COO icon
Cooper Companies
COO
+$7.33M
5
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Financials 3.98%
3 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
101
DELISTED
Aimmune Therapeutics
AIMT
$3.17M 0.23%
293,000
– –
MRUS
102
DELISTED
Merus
MRUS
$2.88M 0.21%
+360,811
New +$3.16M
STE icon
103
Steris
STE
$23.1B
$2.75M 0.2%
+40,000
New +$2.8M
CDTX
104
DELISTED
Cidara Therapeutics
CDTX
$2.58M 0.19%
12,500
– –
SYRE icon
105
Spyre Therapeutics
SYRE
$9.25B
$2.55M 0.19%
+20,964
New +$4.02M
NVCR icon
106
NovoCure
NVCR
$1.91B
$2.5M 0.19%
214,316
– –
SRPT icon
107
Sarepta Therapeutics
SRPT
$1.77B
$2.5M 0.18%
131,000
– –
DVAX
108
DELISTED
Dynavax Technologies
DVAX
$2.41M 0.18%
165,000
– –
DBVT
109
DBV Technologies
DBVT
$847M
$2.38M 0.18%
7,300
– –
ALPN
110
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.25M 0.17%
122,250
– –
ASMB icon
111
Assembly Biosciences
ASMB
$529M
$2.17M 0.16%
32,500
– –
GNCA
112
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.97M 0.15%
60,000
– –
INOV
113
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$1.88M 0.14%
104,302
-322,998
-76% -$5.78M
TTPH
114
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.83M 0.14%
21,250
+1,250
+6% +$115K
CLVS
115
DELISTED
Clovis Oncology, Inc.
CLVS
$1.72M 0.13%
125,000
– –
DMTX
116
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.63M 0.12%
271,370
– –
GBT
117
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.63M 0.12%
98,000
+20,000
+26% +$403K
EGLT
118
DELISTED
Egalet Corporation
EGLT
$1.49M 0.11%
300,000
– –
ICPT
119
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.43M 0.11%
10,000
– –
CHMA
120
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.42M 0.11%
492,500
– –
ANTH
121
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.39M 0.1%
56,250
– –
RLYP
122
DELISTED
RELYPSA INC COM
RLYP
$1.39M 0.1%
+75,000
New +$1.32M
SCYX icon
123
SCYNEXIS
SCYX
$52M
$1.38M 0.1%
7,938
– –
BHC icon
124
Bausch Health
BHC
$2.34B
$1.33M 0.1%
66,100
-19,400
-23% -$549K
DARE icon
125
Dare Bioscience
DARE
$21M
$1.32M 0.1%
5,208
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rock Springs Capital Management held 142 positions worth $1.35B, up 13% from $1.19B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $100M of net new capital in Q2 2016, opening 12 new positions and adding to 63 existing holdings. Its largest new stake was Shire pic: 120,042 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Inovalon Holdings, Inc. Class A Common Stock, an estimated $5.78M trimmed.

  • Rock Springs Capital Management's largest Q2 2016 buy was Shire pic: 120,042 shares worth $22.1M.
  • Rock Springs Capital Management added most to Cigna in Q2 2016, an estimated $11.2M increase.
  • Rock Springs Capital Management's biggest Q2 2016 reduction was Inovalon Holdings, Inc. Class A Common Stock, cutting an estimated $5.78M.
  • Rock Springs Capital Management fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $32.7M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.35B portfolio in Q2 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 5 in Q2 2016.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $1.35B.

Based on Rock Springs Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.